Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic H...(ept as expressly required by law Watsond...),Health

Date:2/12/2008

ept as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of clinical studies, product development efforts and FDA or other regulatory agency approvals or actions; whether the results of clinical trials for silodosin and other information will be sufficient to support approval by FDA and other regulatory authorities; delays regarding the regulatory approval process, including the timing and scope of approval received, if any; market acceptance and continued demand for Watson's products, including silodosin, if approved; our ability to successfully defend and/or enforce our patents and other intellectual property rights against third parties; patents and other intellectual property rights held by competitors and other third parties; successful compliance with FDA and other governmental regulations applicable to Watson's products and/or business; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
2. Watson Launches Generic Biaxin(R) XL
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
6. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
7. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
8. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201